A Kangmei Pharmaceutical booth is seen during a trade and service fair in Beijing on May 31, 2018. A recent trial over the company’s financial practices has raised fresh concerns about the role of independent directors on Chinese boards. Photo: Reuters
Opinion
Opinion
The View
How learning from US best practices can aid China’s corporate fraud fight
- The trial over Kangmei Pharmaceutical’s financial practices and subsequent mass resignation of external directors from 24 listed companies shows the need for reform
- Capital markets remains one area where China can and should emulate the US despite all their tensions
A Kangmei Pharmaceutical booth is seen during a trade and service fair in Beijing on May 31, 2018. A recent trial over the company’s financial practices has raised fresh concerns about the role of independent directors on Chinese boards. Photo: Reuters
